Abstract

Chikungunya virus (CHIKV) is a re-emerging arbovirus known to cause chronic myalgia and arthralgia with high morbidity. CHIKV is now considered endemic in many countries across Asia and Africa. In this study, the susceptibility of various human, mammalian and mosquito cell lines to CHIKV infection was evaluated. CHIKV infection was found to be cell-type dependent and virus strain-specific. Furthermore, SJCRH30 (human rhabdomyosarcoma cell line) was showed to be highly permissive to CHIKV infection, with maximum production of infectious virions observed at 12 h.p.i. Pre-infection treatment of SJCRH30 with various inhibitors of endocytosis, including monodansylcadaverine (receptor-mediated endocytic inhibitor), dynasore (clathrin-mediated endocytic inhibitor), as well as filipin (caveolin-mediated endocytosis inhibitor), resulted in minimal inhibition of CHIKV infection. In contrast, dose-dependent inhibition of CHIKV infection was observed with the treatment of macropinocytosis inhibitor, 5-(N-ethyl-N-isopropyl)amiloride (EIPA). Furthermore, siRNA-mediated knockdown of sortin nexin 9 (SNX9) a protein involved in macropinosome formation, also resulted in a significant dose-dependent reduction in viral titre. By performing a virus entry assay, CHIKV particles were also observed to colocalize with FITC-dextran, a macropinosome marker. This study shows for the first time, that the infectious entry of CHIKV into human muscle cells is mediated by macropinocytosis. Together, the data from this study may pave the way for the development of specific inhibitors that target the entry process of CHIKV into cells.

Highlights

  • Chikungunya virus (CHIKV) is an arthropod-borne virus belonging to genus Alphavirus and family Togaviridae

  • This study revealed the differences in susceptibility of various human, mammalian and mosquito cell lines to CHIKV infection

  • It is imperative to gain a deeper understanding of the pathogenesis of CHIKV infection, in order to drive the development of effective antiviral therapeutics

Read more

Summary

Introduction

Chikungunya virus (CHIKV) is an arthropod-borne virus belonging to genus Alphavirus and family Togaviridae. CHIKV is most commonly transmitted by Aedes (Ae.) mosquitoes. First isolated in 1952 in Tanzania, CHIKV transmission begins with infection of female mosquitoes via a viremic blood-meal taken from a susceptible vertebrate host and subsequent transmission to another vertebrate host [1]. CHIKV-infected individuals may suffer from persistent polyarthralgia and myalgia, often resulting in significant dips in their quality of life. Despite the disease having impacted millions around the world in the last two decades, no antiviral against CHIKV infection is available. CHIKV treatment remains primarily supportive, with key areas of focus being management of clinical symptoms and prevention of vector transmission. It is imperative to gain a deeper understanding of the pathogenesis of CHIKV infection, in order to drive the development of effective antiviral therapeutics

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call